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iacylglycerol (DAG) lipase activity is required for
axonal growth during development and for retrograde
synaptic signaling at mature synapses. This enzyme
synthesizes the endocannabinoid 2-arachidonoyl-glycerol
(2-AG), and the CB1 cannabinoid receptor is also required
for the above responses. We now report on the cloning and
enzymatic characterization of the ﬁrst speciﬁc 
 
sn
 
-1 DAG
lipases. Two closely related genes have been identiﬁed and
their expression in cells correlated with 2-AG biosynthesis
D
 
and release. The expression of both enzymes changes from
axonal tracts in the embryo to dendritic ﬁelds in the
adult, and this correlates with the developmental change in
requirement for 2-AG synthesis from the pre- to the
postsynaptic compartment. This switch provides a possible
explanation for a fundamental change in endocannabinoid
function during brain development. Identiﬁcation of these
enzymes may offer new therapeutic opportunities for a
wide range of disorders.
 
Introduction
 
The identification of the CB1 and CB2 cannabinoid receptors,
activated by the principal psychoactive component of
 
Cannabis sativa
 
, suggests that one or more enzymes synthesize
endogenous ligands for these receptors (Pertwee, 1997;
Di Marzo et al., 1998). An as yet unidentified 
 
sn
 
-1–specific
DAG lipase (DAGL) can catalyze the hydrolysis of DAG to
2-arachidonoyl-glycerol (2-AG), the most abundant endo-
cannabinoid in tissues (Mechoulam et al., 1995; Sugiura et
al., 1995). In the developing brain, pharmacological studies
suggest that DAGL activity is required for axonal growth
and guidance (Brittis et al., 1996), with the 2-AG being
synthesized and activating CB1 receptors in the same “pre-
synaptic” axonal growth cone (Williams et al., 2003).
However, in the adult brain there is a specific postsynaptic
requirement for the synthesis of one or more endocannab-
inoids that act as retrograde messengers on presynaptic CB1
receptors to suppress further transmitter release at both
excitatory and inhibitory synapses (Wilson and Nicoll,
2002). A full elucidation of endocannabinoid signaling in
the developing and adult brain clearly requires the identifi-
cation and characterization of the brain DAGLs.
 
Results and discussion
 
A bioinformatic approach to identify candidate DAGLs
 
When the sequence of a 
 
Penicillium
 
 DAGL (Yamaguchi et al.,
1991) is “blasted” against the human genome, two related
genes (designated 
 
 
 
 and 
 
 
 
) are identified as the only homo-
logues (Fig. 1 a). The encoded gene products are 1,042 (
 
 
 
)
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and 672 (
 
 
 
) amino acids in length and show extensive ho-
mology throughout, but differ in the length of the sequence
that follows the catalytic domain (Fig. 1 a). Both proteins
contain a lipase-3 motif and a serine lipase motif, and they
are predicted to have four transmembrane-spanning do-
mains with the catalytic domain and amino terminus inside
of the cell (Fig. 1 a). The genes are found in a wide range of
species (e.g., chickens, zebrafish, and mice) with a high de-
gree of conservation between man and mouse (97% identity
for 
 
 
 
 and 79% for 
 
 
 
; unpublished data).
 
Enzymatic characterization of the novel genes
 
Transfection of the two novel genes in COS cells led to the
expression of products with appropriate molecular mass (
 
 
 
70
kD for the 
 
 
 
 gene and 
 
 
 
120 kD for the 
 
 
 
 gene) with protein
expression localized to the plasma membrane (Fig. 1, b and c).
COS cells expressing the highest levels of the gene products
(clones 12
 
 
 
 and 15
 
 
 
) were selected for enzymatic character-
ization with a clone that expressed no detectable transgene
taken as a control (clone 7
 
 
 
;
 
 
 
Fig. 1 b). When using 
 
sn
 
-1-
stearoyl-2-[
 
14
 
C]arachidonoyl-glycerol as a substrate, and mea-
suring the 2-[
 
14
 
C]AG released, we confirmed that both
enzymes are mostly expressed in the 10,000 
 
g
 
 membrane frac-
tion (Fig. 2 a), exhibit optimal activity at pH
 
 
 
7 (not depicted),
and follow Michaelis–Menten kinetics, with K
 
m
 
 values in the
range of the possible concentrations of DAGs in animal tis-
sues (154.7 
 
 
 
 19.1 and 74.1 
 
 
 
 4.9 
 
 
 
M for the 
 
 
 
 and 
 
 
 
 form,
respectively; Fig. 2 b). Both enzymes exhibit very little, if any,
monoacylglycerol lipase, phospholipase A
 
1
 
/A
 
2
 
, triacylglycerol
lipase, and anandamide amidase activity (unpublished data).
To investigate their substrate selectivity, three types of radiola-
beled DAG substrates were synthesized. A three- to eightfold
selectivity for the 
 
sn
 
-1 over the 
 
sn
 
-2 position of DAGs (Fig. 2
c) was demonstrated by comparing the rate of the formation
of [
 
14
 
C]oleic acid and 
 
sn
 
-1-[
 
14
 
C]oleoyl-glycerol from 
 
sn
 
-1-
[
 
14
 
C]oleoyl-2-oleoyl-glycerol; or by comparing the rate of
the formation of mono[
 
14
 
C]oleoyl-glycerol from either 
 
sn
 
-
1-[
 
14
 
C]oleoyl-2-oleoyl-glycerol or 
 
sn
 
-1-oleoyl-2-[
 
14
 
C]oleoyl-
glycerol. The similar activities of the enzymes observed when
using as substrates either 
 
sn
 
-1-[
 
14
 
C]oleoyl-2-arachidonyl glyc-
eryl ether, which cannot be hydrolyzed on the 2 position,
or 
 
sn
 
-1-[
 
14
 
C]oleoyl-2-arachidonoyl glycerol, further demon-
strates that the two lipases are selective for the 
 
sn
 
-1 position of
DAGs. Of the two enzymes, the 
 
 
 
 form appears to prefer 
 
sn
 
-
1-oleoyl-2 acyl-glycerols with linoleic 
 
 
 
 oleic 
 
 
 
 arachidonic 
 
 
 
stearic acid on the 2 position, whereas the 
 
 
 
 form appears
to work equally well with all fatty acids (Fig. 2 d and not
depicted). Both enzymes are equally sensitive to Ser/Cys-
hydrolase inhibitors such as 
 
p
 
-hydroxy-mercuri-benzoate and
HgCl
 
2
 
, but not to PMSF. Importantly, both enzymes are in-
hibited by RHC80267, a drug that blocks 2-AG formation
from intact cells (Bisogno et al., 1997; Stella et al., 1997).
Figure 1. Characterization and expression of the novel genes. An alignment between the human   (gi|20521123) and   (gi|21040277) 
gene products is shown in panel a. The four putative transmembrane domains, the serine lipase motif, and the lipase 3 motif are highlighted 
by lines above the sequence, a dotted line, and a line below the sequence, respectively. Mutated amino acids are denoted with an asterisk. 
A Western blot analysis (with molecular mass markers in kD) of control and transfected COS cells expressing the   and   gene products, 
including the mutated clones, is shown in panel b. The localization of the   transgene in transfected COS cells is shown in panel c.T
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Glutathione and Ca
 
2
 
 
 
 stimulate both enzymes (Fig. 2 e).
Based on homology with other serine lipases, two of the three
amino acids that likely constitute the “catalytic triad” can
readily be identified as serine 443 and aspartic acid 495 in the
 
 
 
 form of the enzyme (Fig. 1 a). Accordingly, substitution of
the serine (clone 11-11
 
 
 
) or aspartic acid (clone 3-9
 
 
 
) with
alanines abolished enzymatic activity (Fig. 2 a). Based on these
results, we can conclude that the products of the genes
are  specific 
 
sn
 
-1-DAGLs; therefore, we designate them as
DAGL
 
 
 
 and DAGL
 
 
 
.
 
Both enzymes contribute to the Ca
 
2
 
 
 
-dependent 
biosynthesis/release of endocannabinoid 2-AG 
from intact cells
 
In agreement with the Ca
 
2
 
 
 
 requirement of the novel en-
zymes, and with the Ca
 
2
 
 
 
 dependence of 2-AG biosynthesis
in neurons (Bisogno et al., 1997; Stella et al., 1997), iono-
mycin stimulation of clone 12
 
 
 
 or 15
 
 
 
 cells led to the pro-
duction, and release into the media, of significantly higher
amounts of 2-AG than control COS cells (Fig. 2 f). A strong
correlation between the expression of the novel genes and
endogenous DAGL activity was found in a wide range of cell
types (e.g., N18TG2 neuroblastoma, C6 glioma, RBL-2H3
basophilic leukemia, human Caco-2, and embryonic kidney
HEK-293 cells; unpublished data). More importantly, tet-
rahydrolipstatin (THL), a second DAGL inhibitor (Lee et
al., 1995), potently inhibited both DAGL
 
 
 
 and DAGL
 
 
 
from clone 12
 
 
 
 and 15
 
 
 
 cell homogenates (IC
 
50
 
 
 
 
 
 60 and
100 nM, respectively). THL (5-min preincubation at 1 
 
 
 
M)
also decreased the ionomycin-induced release of 2-AG from
intact N18TG2, C6, and RBL-2H3 cells (66.7 
 
 
 
 5.9, 93.5 
 
 
 
7.3, and 99.2 
 
 
 
 10.1% inhibition, respectively; means 
 
 
 
SEM, 
 
n 
 
  
 
3, P 
 
  
 
0.01), as well as in clone 12
 
 
 
 (Fig. 2 f).
Figure 2. Enzymatic characterization 
of the new lipase gene products 
expressed in COS cells (clones 12  
and 15 ). (a) Subcellular fractionation 
of the enzymes using sn-1-stearoyl-2-
[
14C]arachidonoyl-glycerol as a substrate. 
Controls included two clones expressing 
the highest levels of the   gene product 
with single point mutations in Asp 494 
to Ala (clone 3-9 ) and Ser 443 to Ala 
(clone 11-11 ). Activity is expressed as 
fold over the activity in fractions from 
a clone transfected with the   construct 
that expressed no detectable transgene 
(clone 7 , control cells). (b) Lineweaver–
Burk profiles of the activities in the 
10,000 g pellets from clones 12  and 
15 . Data points were subtracted from 
the activity found in control cells (clone 
7 ). Vmax values were 33.3   4.5 and 
3.45   0.16 nmol min
 1 mg protein
 1 
for the   and   form, respectively. 
(c) Selectivity of the two DAGLs for the 
sn-1 position of DAGs. The rate of 
formation is shown for: (1) [
14C]oleic 
acid (sn-1 bars) and sn-1-[
14C]oleoyl-
glycerol (sn-2 bars) from sn-1-[
14C]oleoyl-
2-oleoyl-glycerol, this indicates sn-1 
and sn-2 selectivity, respectively; (2) 
mono[
14C]oleoyl-glycerol from either 
sn-1-[
14C]oleoyl-2-oleoyl-glycerol (sn-2 
bars) or sn-1-oleoyl-2-[
14C]oleoyl-glyc-
erol (sn-1 bars), this indicates sn-2 and 
sn-1 selectivity, respectively; and (3) 
[
14C]oleic acid from either sn-1-[
14C]ole-
oyl-2-arachidonyl glyceryl ether (ether 
bars), or sn-1-[
14C]oleoyl-2-arachidonoyl 
glycerol (ester bars), this indicates sn-1 
selectivity, without and with possible 
interference from sn-2 selectivity, 
respectively. (d) Rate of formation of [
14C]oleic acid using DAG substrates with different fatty acids on the 2-position. (e) Effect of inhibitors, 
glutathione (GSH), and calcium on enzyme activity assessed using sn-1-[
14C]oleoyl-2-arachidonoyl-glycerol as substrate. 1 mM PMSF; 
1 mM p-hydroxy-mercuri-benzoate (p-HMB); 5 mM HgCl2; and 100  M RHC80267. The concentrations of CaCl2 in the assay buffer were 1, 
10, 100, 1,000, and 10,000  M. (f) Formation of 2-AG from intact COS cells (nontransfected or clones 12  and 15 ), stimulated for 20 min 
with vehicle (DMSO, 0.1%), 4  M ionomycin, or ionomycin   1  M THL after a 5-min preincubation with THL. 2-AG levels were measured 
in cells plus medium (total) by liquid chromatography-mass spectrometry. Results are expressed as a percentage of 2-AG formation from 
vehicle-stimulated cells (12.1   4.3 pmol/mg extracted lipids). In one set of experiments, the amounts of 2-AG produced after ionomycin 
stimulation were measured separately in cells and medium, and the percentage of the amount of 2-AG found in the medium (extracellular) 
is shown. Data are means   SEM of n   4. *, P   0.05, control cells; 
#, P   0.05, iono only (total), t test.T
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FGF2 stimulates neurite outgrowth from cerebellar neurons
via a pathway that requires DAGL activity to generate 2-AG
and the consequent activation of the CB1 receptor (Wil-
liams et al., 2003). THL inhibited the neurite outgrowth
stimulated by FGF2 with no effect on the response stimu-
lated by a CB1 agonist or brain-derived neuronotrophic fac-
tor (BDNF; Fig. 3), demonstrating that it is acting specifi-
cally, and upstream of the CB1 receptor, in the FGF
signaling pathway. Thus, the novel enzymes make and re-
lease 2-AG as endocannabinoid, and THL is a useful tool to
investigate the cellular function of the two enzymes.
A switch in enzyme expression from axons to dendrites 
during development
The expression of the novel sn-1-DAGLs will determine
when and where they can make and release 2-AG in the de-
veloping and adult brain. In general, antibodies to DAGL 
and   showed the same qualitative staining pattern, demon-
strating that they are normally coexpressed; and similar
staining patterns were seen with three independent antisera
to DAGL  (unpublished data). We found that all develop-
ing axonal tracts examined coexpress the enzymes. For ex-
ample, in the mouse at embryonic day 10, DAGL  and DA-
GL  are expressed in axons crossing the floor plate of the
spinal cord (Fig. 4, a–c). At day 14, DAGL  can be seen to
specifically label the retinal ganglion fiber tract and also the
optic nerve (Fig. 4 d). A similar, but less pronounced, stain-
ing was seen for DAGL  (unpublished data). Remarkably,
both enzymes are absent from axonal tracts in the adult
mouse brain, with this shown for DAGL  in the optic and
anterior commissures in Fig. 4, e and f. This contrasted with
the very strong staining of both regions with antibodies to
the CB1 receptor (Fig. 4, g and h). In the cerebellum, the
highest levels of DAGL  and DAGL  are seen in the den-
dritic field with staining also apparent in the deep cerebellar
nuclei (Fig. 4, i and j); however, both enzymes are again ab-
sent in the axonal tracts. A high power image of DAGL  ex-
pression within the Purkinje cell dendritic field of the
cerebellum clearly shows that the enzyme is specifically ex-
pressed in the tubular-like structures that characterize the
dendritic tree of the Purkinje cell (Fig. 4 k). The staining for
DAGL  was qualitatively similar but considerably less pro-
nounced than that for DAGL  (Fig. 4, i and j), suggesting a
substantial down-regulation of the   form of the enzyme
during development. Given the maintained expression of
high levels of DAGL  in the adult nervous system, we as-
sessed the relative level of transcripts for the gene in various
adult tissues in the mouse and human by TaqMan RT-PCR.
In the mouse, the highest levels of transcripts were found in
the nervous system, with barely detectable levels found in
the skin, heart, lung, and various other tissues (Fig. 5),
which is in agreement with the highest relative abundance of
2-AG and other 2-acylglycerols in the rodent brain (Kondo
et al., 1998). In the human, high levels of expression were
again found in the brain, relative to most tissues, with high
levels also noted in the pancreas (Fig. 5). The pancreatic ex-
pression is of interest given the established role for DAGL
activity in amylase secretion in this tissue (Hou et al., 1997).
In summary, this study is the first to report the identifica-
tion of specific sn-1 DAGLs playing a major role in biosyn-
thesizing the endocannabinoid 2-AG. Expression studies
Figure 3. THL inhibits the neurite outgrowth response stimulated 
by FGF2. Rat cerebellar neurons were isolated at postnatal day 2 
and cultured over monolayers of 3T3 cells in control media or media 
supplemented with 5 ng/ml FGF2, 5 ng/ml BDNF, or 0.2  M 
WIN55,2122-2 as indicated. The experiments were done in the 
absence (white bars) and presence (black bars) of 10  M THL. After 
18 h, the cultures were fixed and stained for GAP-43, and the mean 
length of the longest neurite was determined from  140 neurons 
under each culture condition. For the control and FGF2 data, results 
were pooled from three independent experiments. For the BDNF 
and CB1 agonist data, the results were pooled from two independent 
experiments. Bars show SEM. Dose–response experiments (not 
depicted) indicated an IC50   2  M for the inhibition by THL of 
FGF2 response.
Figure 4. Expression of the novel lipases in the mouse nervous 
system. DAGL  (a) and DAG  (b) are expressed in neurofilament-
positive axonal tracts (c) in the embryonic spinal cord (day 10). 
DAGL  is expressed in the embryonic retinal ganglion fiber layer 
and optic nerve at day 14 (d). Note the lack of expression of DAGL  
in the optic (e) and anterior commissures (f) in the adult. This contrasts 
with strong staining for the CB1 receptor in these tracts (g and h). 
DAGL  (i) and DAGL  (j) expression in the adult cerebellum is 
restricted to the deep cerebellar nuclei and synaptic fields, including 
the Purkinje cell dendrites (k). Bar: (a–c)  130  m; (d)  220  m; 
(e–j)  500  m; (k)  20  m.T
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have revealed that although both enzymes are expressed in
axonal tracts during development, expression in the adult
becomes restricted to synaptic fields. It is also clear that in
the adult cerebellum, expression within a synaptic field can
be restricted to the dendritic compartment. Therefore, the
ability of these enzymes to make and release 2-AG is tempo-
rally and spatially regulated in the brain in a manner that
correlates well with two of the key functions of the endocan-
nabinoid signaling system. In fact, in the developing em-
bryo, the enzymes are available within a growth cone to
make 2-AG able to act in an autocrine way on CB1 recep-
tors to promote axonal growth and guidance (Williams et
al., 2003). In contrast, in the adult, the enzymes are lost
from axonal tracts but remain expressed in synaptic fields. In
the case of the cerebellar Purkinje cell, this expression is lo-
calized to the postsynaptic dendrite, and this correlates with
the postsynaptic requirement for the synthesis of an en-
docannabinoid as a retrograde messenger for depolarization-
induced suppression of excitatory neurotransmission at this
synapse (Kreitzer and Regehr, 2001; Diana et al., 2002).
With the identification of the first DAGLs, it will now be
possible to test their importance in physiologically relevant
endocannabinoid signaling pathways and to evaluate their
potential as therapeutic targets. In the latter context, there is
a growing interest in 2-AG/CB1 signaling in terms of thera-
pies for a range of conditions including neurodegenerative
diseases (Di Marzo et al., 2000; Panikashvili et al., 2001),
obesity (Di Marzo et al., 2001), and the extinction of aver-
sive memories (Marsicano et al., 2002).
Materials and methods
Cloning and expression of DAGLs
A full-length clone of the human   gene (gi|20521122) was obtained from
the Kazusa DNA Research Institute (KIAA0659), and the mouse   gene
(gi|16359288) was obtained from I.M.A.G.E. Consortium (4921222). The
coding sequence for the   gene was amplified by PCR and inserted into
pcDNA3.1D/V5-His-TOPO (Invitrogen) to generate an expression con-
struct with an in-frame 3  V5 epitope tag. The coding sequence for the  
gene was amplified by PCR and subcloned into pCMV-Tag4A (Stratagene)
using the NotI and XhoI restriction sites, in-frame with a 3  FLAG epitope
tag. Single point mutations in the   gene were generated using the
QuikChange Site-Directed Mutagenesis kit (Stratagene). Plasmids were
transfected into COS-7 cells using lipofectamine plus (Invitrogen), and sta-
ble transfected clones were selected using G418. For Western blotting,
equal amounts of protein lysate were separated on SDS–polyacrylamide
gels and transferred to nitrocellulose Hybond ECL (Amersham Bio-
sciences). Primary antibodies used were mouse anti-V5 (Invitrogen) at
1:5,000 and mouse anti-Flag (Stratagene) at 1:1,000. The secondary anti-
body was anti–mouse HRP (Vector Laboratories) used at 1:3,000.
Synthesis of substrates
In brief, the compounds were obtained from the R ( ) solketal esterified
with either unlabeled or 
14C-labeled oleic acid using N’-(3-dimethylamino-
propyl)-N-ethylcarbodiimide hydrochloride/4-dimethylaminopyridin, and
deprotecting the acetonide with hydrochloride/methanol. The primary al-
coholic group was protected selectively with triisopropylsilyl chloride,
whereas the free secondary alcohol was esterified with various fatty acids,
either unlabeled or 
14C-labeled. Finally, the sn-1,2-diacyl-glycerol with
two different acyl groups in position sn-1 and 2 was obtained by removing
selectively the sylyl group with tetrabutylammonium fluoride/acetic acid.
To prepare sn-1-[
14C]oleoyl-2-arachidonyl glyceryl ether, the previously
prepared 2-AG ether (noladin) was esterified with [
14C]oleic acid using N’-
(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride /4-dimethyl-
aminopyridin. 2-[
3H]arachidonoyl-glycerol and arachidonoyl-[
14C]etha-
nol-amide were synthesized as described previously (Bisogno et al., 1997)
with minor modifications.
Enzyme assays
Confluent cells were harvested in Tris-HCl buffer, pH 7, and homogenized
in a homogenizer (Dounce). The homogenates were centrifuged at 4 C se-
quentially at 800 g (5 min), 10,000 g (25 min), and 100,000 g (70 min).
Each fraction or, for most of the experiments, the 10,000-g fraction was in-
cubated at pH 7.0 (or in citrate 50 mM or Tris-HCl 50 mM buffers at differ-
ent pH values) at 37 C for 15 min, with different radiolabeled substrates
(i.e., for DAGL activity, with various synthetic 
14C-labeled DAGs [1.0 mCi/
mmol, 50  M] or with sn-1-stearoyl-2-[
14C]arachidonoyl-glycerol from
Amersham Biosciences, 56.0 mCi/mmol, at different concentrations; for
monoacylglycerol lipase activity, with synthetic 2-[
3H]arachidonoyl-glyc-
erol, 1.0 mCi/mmol, 50  M; for triacylglycerol lipase activity, with 1,2,3-
tri-[
14C]oleoyl-glycerol from NEN, 100.0 mCi/mmol, 50  M; for phospho-
lipase A1/A2 activity, or sn-1-[
14C]oleoyl-2-[
14C]oleoyl-phosphatidylcholine
from NEN, 104.0 mCi/mmol, 20  M; and for fatty acid amide hydrolase
activity, with synthetic arachidonoyl-[
14C]ethanolamide, 5.0 mCi/mmol,
25  M). After the incubation, lipids were extracted three times with 2 vol
chloroform/methanol 2:1 (by vol), and the extracts were lyophilized under
vacuum. Extracts were fractionated by TLC on silica on polypropylene
plates using chloroform/methanol/NH4OH (85:15:0.1, by vol) as the elut-
ing system. Under these conditions, the migration index of free fatty acids,
monoacylglycerols, and diacylglycerols was 0.25, 0.65, and 0.9, respec-
tively; the migration index of phospholipids and triacylglycerols was 0.05
and 1.0, respectively. Bands corresponding to each class of lipids were
cut, and their radioactivity was counted with a  -counter. Using sn-1-
stearoyl-2-[
14C]arachidonoyl-glycerol as the substrate, the DAGL reaction
rate was linear up to 20 min and reached a plateau after 30 min, with both
DAGL  and  . Saturation of DAGL  and   activity was reached with 500
and 400  M, respectively, when using sn-1-stearoyl-2-[
14C]arachidonoyl-
glycerol as the substrate.
Figure 5. Relative expression of mouse and human DAGL  in 
various adult tissues. TaqMan RT-RCR was used to measure the relative 
level of mouse (top) and human (bottom) DAGL  transcripts in various 
tissues as indicated. In both instances, the number of mRNA copies 
detected for DAGL  was divided by the number of mRNA copies of 
GAPDH and  -actin detected in each sample. The average of these 
two figures are plotted. For the human, data were obtained for two 
males and two females; there were no obvious gender differences, 
and the results from all four individuals were pooled.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
468 The Journal of Cell Biology | Volume 163, Number 3, 2003
Intact cell stimulation and 2-AG analyses
Confluent cells were stimulated for 20 min at 37 C with either vehicle or 4
 M ionomycin or 1  M ionomycin   THL, after a 5-min preincubation,
with THL in DME medium without serum. Immediately after the stimula-
tion, cells, medium, or cells plus medium were extracted three times with
2 vol chloroform/methanol 2:1 (by vol), and the extracts were lyophilized
under vacuum. Each extract was purified by open bed chromatography
over silica columns, followed by 2-AG quantification by means of isotope
dilution atmospheric pressure chemical ionization–liquid chromatogra-
phy–mass spectrometry (Marsicano et al., 2002).
Immunohistochemistry
Rabbit antibodies, raised and affinity purified against the GASPTKQD-
DLVISAR epitope in DAGL , and the SSDSPLDSPTKYPTL epitope in DA-
GL , were used at 1.5–3.0  g/ml for immunostaining. An affinity-puri-
fied antibody against the CB1 receptor (PA1-745; Affinity BioReagents,
Inc.) was used at 20  g/ml IgG. An antineurofilament monoclonal anti-
body (N5264; Sigma-Aldrich) was used at a dilution of 1:1,000. 6- m
sections of formalin-fixed, paraffin wax–embedded tissues were sub-
jected to heat-mediated antigen retrieval to disclose antigenic sites be-
fore being incubated in primary antibody solutions overnight at 4 C. Af-
ter washing, the sections were incubated with biotinylated secondary
antibodies (E0432 and E0433; Dakopatts) followed by detection with an
HRP-streptavidin-biotin kit (model K377; Dakopatts). To visualize the V5
epitope tag, cells were fixed with 4% PFA and processed for indirect im-
munofluorescence. Cells were permeabilized with 0.2% Triton X-100/
PBS and stained with mouse anti-V5 primary antibody at 1:200, followed
by Alexa Fluor 488 goat anti–mouse IgG secondary (Molecular Probes) at
1:2,000. Slides were viewed on a microscope (model Axiovert 135; Carl
Zeiss MicroImaging, Inc.), using 10 /0.25 Achrostigmat or 63 /1.4 Oil
Pan-Apochromat lens. Images were captured with an AxioCam using
KS300 software (Carl Zeiss MicroImaging, Inc.). Images were processed
in Adobe Photoshop, with brightness and contrast being the only adjust-
ments made.
Neurite outgrowth studies
Neurite outgrowth studies and reagents used therein were as described
previously (Williams et al., 2003).
Real-time RT-PCR analysis of DAGL  expression 
in various tissues
TaqMan RT-PCR for DAGL  was performed essentially as described previ-
ously (Bond et al., 2002). Primers were based on sequences encoded by
exon 19; for the mouse, the forward and reverse primers were ttcgccgagt-
tcattgacag and tctcaggcaccatcatgca. For the human, the forward and re-
verse primers were cctcttcaacctggacagcaa and gggccctcagcgtagtca. To
normalize data and to correct for variations in RNA and/or cDNA quality
and quantity, parallel TaqMan assays were run for two housekeeping
genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and  -actin.
TaqMan analysis was performed by K. Philpott and R. Davies (GlaxoSmith-
Kline, Harlow, UK).
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